非癌症患者肾上腺偶发瘤的18F-FDG-PET/CT评估
该回顾性研究纳入117例非癌症患者的肾上腺肿块,评估18F-FDG-PET/CT鉴别良恶性的效能。肝脏SUV比值最佳阈值2.5时灵敏度85%、特异度90%;血池SUV比值阈值3.4时灵敏度83%、特异度90%。
要点
- 18F-FDG-PET/CT可辅助鉴别非癌症患者肾上腺肿块良恶性。
- 肝脏SUV比值阈值2.5:灵敏度85%,特异度90%。
- 血池SUV比值阈值3.4:灵敏度83%,特异度90%。
核心结论
- 18F-FDG-PET/CT结合其他临床评估,对非癌症患者肾上腺肿块评估有价值。
研究设计与样本
- 2010-2019年学术机构回顾性病历审查,纳入117例非癌症患者(无癌症史或癌症缓解≥5年)的117个肾上腺肿块,均有病理诊断或≥12个月影像随访。
关键数值与推荐
- 肝脏SUV比值最佳阈值2.5:灵敏度85%,特异度90%,7例假阴性(包括3例肾上腺皮质癌)。
- 血池SUV比值最佳阈值3.4:灵敏度83%,特异度90%,8例假阴性(包括4例肾上腺皮质癌)。
临床怎么用
- 在非癌症患者肾上腺肿块评估中,可结合18F-FDG-PET/CT的肝脏或血池SUV比值辅助鉴别良恶性。
局限性
- 回顾性研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Adrenal tumors in noncancer patients are common. OBJECTIVE: Evaluate performance of 18F-fluorodeoxyglucose positron emission tomography computed tomography (18F-FDG-PET/CT) in distinguishing between benign and malignant adrenal tumors. DESIGN: Retrospective chart review 2010-2019. SETTING: Academic institution. PATIENTS: One hundred and seventeen noncancer patients, defined as having no history of cancer or with cancer in remission for ≥5 years, completed 18F-FDG-PET/CT to evaluate adrenal masses, with pathologic diagnoses or imaging follow-up (≥12 months). INTERVENTION: 18F-FDG-PET/CT of 117 indeterminate adrenal masses. MAIN OUTCOME MEASURES: Receiver operator characteristic curve of the ratios of adrenal lesion standardized uptake value (SUV)max to liver SUVmean and of adrenal lesion SUVmax to aortic arch blood pool SUVmean were constructed. RESULTS: Seventy benign and 47 malignant masses (35 adrenocortical carcinomas [ACCs], 12 adrenal metastases) were identified. Malignant masses had higher median liver SUV and blood pool SUV ratios than benign masses (6.2 and 7.4 vs 1.4 and 2.0, P < .001). Median liver and blood pool SUV ratios of ACC (6.1 and 7.3, respectively) and metastases (6.7 and 7.7, respectively) were higher than those of than adenomas (1.4 and 2.2, P < .05 for all comparisons). Optimal liver SUV ratio to discern between benign and malignant masses was 2.5, yielding 85% sensitivity, 90% specificity, and 7 false negative results (including 3 ACCs). Optimal blood pool SUV ratio was 3.4, yielding 83% sensitivity, 90% specificity, and 8 false negative results (including 4 ACCs). CONCLUSION: When used in conjunction with other clinical assessments, 18F-FDG-PET/CT can be a valuable tool in evaluating adrenal masses in noncancer patients.
引用
- He X, Caoili EM, Avram AM, et al. 18F-FDG-PET/CT Evaluation of Indeterminate Adrenal Masses in Noncancer Patients. J Clin Endocrinol Metab. 2021. PMID: 33524123. doi:10.1210/clinem/dgab005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。